Post-operative urinary retention is impacted by neuromuscular block reversal agent choice : A retrospective cohort study in US hospital setting
Copyright © 2023 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Author(s). Published by Elsevier Inc. All rights reserved..
STUDY OBJECTIVE: Perioperative neuromuscular blocking agents are pharmacologically reversed to minimize complications associated with residual neuromuscular block. Neuromuscular block reversal with anticholinesterases (e.g., neostigmine) require coadministration of an anticholinergic agent (e.g., glycopyrrolate) to mitigate muscarinic activity; however, sugammadex, devoid of cholinergic activity, does not require anticholinergic coadministration. Single-institution studies have found decreased incidence of post-operative urinary retention associated with sugammadex reversal. This study used a multicenter database to better understand the association between neuromuscular block reversal technique and post-operative urinary retention.
DESIGN: Retrospective cohort study utilizing large healthcare database.
SETTING: Non-profit, non-governmental and community and teaching hospitals and health systems from rural and urban areas.
PATIENTS: 61,898 matched adult inpatients and 95,500 matched adult outpatients.
INTERVENTIONS: Neuromuscular block reversal with sugammadex or neostigmine plus glycopyrrolate.
MEASUREMENTS: Incidence of post-operative urinary retention by neuromuscular block reversal agent and the independent association of neuromuscular block reversal technique and risk of post-operative urinary retention.
MAIN RESULTS: The incidence of post-operative urinary retention was 2-fold greater among neostigmine with glycopyrrolate compared to sugammadex patients (5.0% vs 2.4% inpatients; 0.9% vs 0.4% outpatients; both p < 0.0001). Multivariable logistic regression identified reversal with neostigmine to be independently associated with greater risk of post-operative urinary retention (inpatients: odds ratio, 2.20; 95% confidence interval, 2.00 to 2.41; p < 0.001; outpatients: odds ratio, 2.57; 95% confidence interval, 2.13 to 3.10; p < 0.001). Post-operative urinary retention-related visits within 2 days following discharge were five-fold higher among those reversed with neostigmine than sugammadex among inpatients (0.05% vs. 0.01%, respectively; p = 0.018) and outpatients (0.5% vs. 0.1%; p < 0.0001).
CONCLUSION: Though this study suggests that neuromuscular block reversal with neostigmine can increase post-operative urinary retention risk, additional studies are needed to fully understand the association.
| Errataetall: |
ErratumIn: J Clin Anesth. 2024 Mar 18;:111423. - PMID 38503680 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Journal of clinical anesthesia - 93(2024) vom: 25. März, Seite 111344 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bash, Lori D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 19.03.2024 published: Print-Electronic ErratumIn: J Clin Anesth. 2024 Mar 18;:111423. - PMID 38503680 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jclinane.2023.111344 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364990597 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364990597 | ||
| 003 | DE-627 | ||
| 005 | 20240320233705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jclinane.2023.111344 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM364990597 | ||
| 035 | |a (NLM)38007845 | ||
| 035 | |a (PII)S0952-8180(23)00294-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bash, Lori D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-operative urinary retention is impacted by neuromuscular block reversal agent choice |b A retrospective cohort study in US hospital setting |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: J Clin Anesth. 2024 Mar 18;:111423. - PMID 38503680 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a STUDY OBJECTIVE: Perioperative neuromuscular blocking agents are pharmacologically reversed to minimize complications associated with residual neuromuscular block. Neuromuscular block reversal with anticholinesterases (e.g., neostigmine) require coadministration of an anticholinergic agent (e.g., glycopyrrolate) to mitigate muscarinic activity; however, sugammadex, devoid of cholinergic activity, does not require anticholinergic coadministration. Single-institution studies have found decreased incidence of post-operative urinary retention associated with sugammadex reversal. This study used a multicenter database to better understand the association between neuromuscular block reversal technique and post-operative urinary retention | ||
| 520 | |a DESIGN: Retrospective cohort study utilizing large healthcare database | ||
| 520 | |a SETTING: Non-profit, non-governmental and community and teaching hospitals and health systems from rural and urban areas | ||
| 520 | |a PATIENTS: 61,898 matched adult inpatients and 95,500 matched adult outpatients | ||
| 520 | |a INTERVENTIONS: Neuromuscular block reversal with sugammadex or neostigmine plus glycopyrrolate | ||
| 520 | |a MEASUREMENTS: Incidence of post-operative urinary retention by neuromuscular block reversal agent and the independent association of neuromuscular block reversal technique and risk of post-operative urinary retention | ||
| 520 | |a MAIN RESULTS: The incidence of post-operative urinary retention was 2-fold greater among neostigmine with glycopyrrolate compared to sugammadex patients (5.0% vs 2.4% inpatients; 0.9% vs 0.4% outpatients; both p < 0.0001). Multivariable logistic regression identified reversal with neostigmine to be independently associated with greater risk of post-operative urinary retention (inpatients: odds ratio, 2.20; 95% confidence interval, 2.00 to 2.41; p < 0.001; outpatients: odds ratio, 2.57; 95% confidence interval, 2.13 to 3.10; p < 0.001). Post-operative urinary retention-related visits within 2 days following discharge were five-fold higher among those reversed with neostigmine than sugammadex among inpatients (0.05% vs. 0.01%, respectively; p = 0.018) and outpatients (0.5% vs. 0.1%; p < 0.0001) | ||
| 520 | |a CONCLUSION: Though this study suggests that neuromuscular block reversal with neostigmine can increase post-operative urinary retention risk, additional studies are needed to fully understand the association | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Glycopyrrolate | |
| 650 | 4 | |a Neostigmine | |
| 650 | 4 | |a Neuromuscular block reversal | |
| 650 | 4 | |a Postoperative urinary retention | |
| 650 | 4 | |a Sugammadex | |
| 650 | 7 | |a Neostigmine |2 NLM | |
| 650 | 7 | |a 3982TWQ96G |2 NLM | |
| 650 | 7 | |a Sugammadex |2 NLM | |
| 650 | 7 | |a 361LPM2T56 |2 NLM | |
| 650 | 7 | |a Neuromuscular Nondepolarizing Agents |2 NLM | |
| 650 | 7 | |a Glycopyrrolate |2 NLM | |
| 650 | 7 | |a V92SO9WP2I |2 NLM | |
| 650 | 7 | |a Cholinesterase Inhibitors |2 NLM | |
| 700 | 1 | |a Turzhitsky, Vladimir |e verfasserin |4 aut | |
| 700 | 1 | |a Mark, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Hofer, Ira S |e verfasserin |4 aut | |
| 700 | 1 | |a Weingarten, Toby N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical anesthesia |d 1996 |g 93(2024) vom: 25. März, Seite 111344 |w (DE-627)NLM013003399 |x 1873-4529 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2024 |g day:25 |g month:03 |g pages:111344 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jclinane.2023.111344 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2024 |b 25 |c 03 |h 111344 | ||